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Highlights: 
 Livergol (LG), which is the extract of Silybum marianum and commonly known as milk 
thistle possess hepatoprotective effect. 
 The aim of this work is to evaluate the hepatoprotective effect of LG loaded in MEs 
and to increase the oral bioavailability of LG in mice. 
 Orally administered LG significantly suppresses Bromobenzene (BB)-induced 
increases in serum activity of enzymes AST, ALT, ALP.  
 Treatment with LG has improved hepatic damages due to BB severe degeneration and 
vacuolation of hepatocytes. 
 Based on the results the efficacy of LG in MEs showed better drug solubility and 
permeability which lead to improve drug absorption among different biological 
membranes. 
 The hepatoprotective effect of this formulation against BB toxicity has been conducted 
through the control release, high diffusion and absorption rates and improve and 
increase in oral bioavailability of active pharmaceutical agents. 
 
ABSTRACT 
Livergol (LG), which is the extract of Silybum marianum and commonly known as milk thistle 
possess hepatoprotective effect and have got licensed for sale in Iran and other countries. LG was 
evaluated for its capacity to counteract the toxic effects of bromobenzene (BB) on mouse liver. The 
bioactive component of this plant is known to reinforce naturally occurring liver function through 
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antioxidant activity, the stimulation of bile production and regeneration by the liver organ, resulting in 
enhanced protection against toxicants, hepatitis, and cirrhosis. The major bioactive components of this 
product are the flavonolignan ssilibinin, silidianin, silicristin, and isosilibinin. Mice were treated for 
10 days with daily gavage of microemulsions (MEs), into which 0-400 mg/kg LG was dispersed. 0.36 
ml/kg BB was injected intraperitoneally (ip) to each animal on day 10, followed by sacrifice on day 
11, and histological evaluation of hematoxylin-eosin (HE)‐stained liver tissue samples, afterwards 
followed by evaluation liver enzymes level, aminotransferase (AST), alanine aminotransaminase 
(ALT) and alkaline phosphatase (ALP) activities. Significant suppression of BB-mediated damage to 
liver tissue, and increased in AST, ALT, and ALP level was observed to occur dose-responsively with 
LG administration, suggesting a use for LG as a chemoprotectant for persons chronically exposed to 
industrial solvents. 
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1. Introduction 
 
    Dramatic increases in use of herbal formulations for the prevention and long term 
management of a wide range of diseases have occurred during the past several years. This is 
partly due to a combination of market-driven factors, including lower cost and, in many 
cases a lower incidence of adverse effects in comparison to pharmaceutical drugs. Added to 
this, government regulatory constraints on the manufacturing and sale of naturally occurring 
agents is often less stringent than with other medical products. 
    Healthcare providers often find that patient compliance in adherence to a particular course 
of treatment may be substantially better when natural products, particularly extracts of 
medicinal plants extracts, are part of the regimen. Nevertheless, the increasingly widespread 
integration of such products into “mainstream” medicine provides an incentive to conduct 
stringent toxicological analyses on these agents incidental to their clinical use. 
    The present investigation evaluates the capacity of LG, a commercially available product 
made from extract of Silybum marianum (milk thistle) fruit, to protect mouse liver from acute 
damage by BB, a highly toxic organic solvent. previously, LG has shown efficacy in 
protection of the liver against toxicant exposure[1], acute and chronic hepatitis[2], and 
cirrhosis[3]. It has also been shown to directly promote hepatic tissue regeneration, increasing 
production of bile and endogenous antioxidants[4].  
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    In these experiments, mice were treated with selected dosages of LG and were challenged 
with BB, also known as bromobenzol, a highly toxic organic solvent. The primary 
mechanism of its hepatotoxicity occurs as a result of hepatic phase I metabolites produced 
during initial degradation of the compound by liver cells[5, 6]. Further degradation of these 
compounds produce hepatic phase II products, such as bromophenolisomers, which are 
highly nephrotoxic[7], and may cause kidney damage. 
    Authors of this report have previously demonstrated the nephroprotective capacity of 
Cassia fistula (golden shower tree) fruit in BB-exposed mice[8], the mutagenic effects of 
Artemisia dracunculus (Tarragon), a widely used dietary herb [9, 10], and Dillsun, an oleo 
extract of the herb Anethumgraveolens, commonly used in Iran to improve liver function[11] 
.Previous research by these authors has further demonstrated the dermal protective effects 
and toxigenic profiles of quince seed mucilage[12], and of sour cherry seed oils and 
flavonoids [13, 14]. 
    The aim of this work is to find out the toxicological profile of milk thistle that may aid in 
its clinical use by healthcare professionals. Mice were administered selected dosages of a 
microemulsion of milk thistle extract (LG). Subsequently, they were challenged with BB, and 
evaluated for pathological elevation in serum levels of three liver enzymes, known to increase 
in response to hepatotoxic influences, and for adverse effects on liver tissue integrity. The 
extent to which both of these outcomes were suppressed in LG-treated animals is an indicator 
of the protective and therapeutic efficacy of the plant in response to hepatotoxins. 
 
2. Materials and methods 
  2.1. Animals 
    Swiss albino male mice were used in these experiments with an average weight of 25 ± 5 g. 
They were fed regular rodent chow pellets ad libitum with free access to tap water and were 
maintained at an ambient temperature of 25 ± 2˚C, with a relative humidity of 55 ± 5%, and a 
12-hour light-dark cycle. These animals were acclimatized for one week prior to initiation of 
experiments. The mice were handled and received humane care in compliance with the 
principles of laboratory animal care formulated by the National Society for Medical Research 
and Guide for the Care and Use of Laboratory Animals prepared by the United States 
National Academy of Sciences, and published by the U.S. National Institutes of Health 
(Publication No. NIH 85-23, revised in 1996). All the protocols for their use in this 
investigation were approved by the institutional review board (IRB) of Ahvaz Jundishapur 
University of Medical Sciences (approval number: u-91134). 
2.2. Microemulsions Preparation 
   The microemulsions vehicle containing LG was dispersed for oral gavage administration to 
the mice was prepared from a system composed of olive oil (commercial grade, purchased 
locally in Iran), Tween 80 (Sigma-Aldrich, St. Louis, MO, USA), and Span 20 (Sigma-
Aldrich) (1:1 ratio), as surfactant and co-surfactant and propylene glycol (Sigma) (3:1 ratio of 
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surfactant/co-surfactant). Pseudo-ternary phase diagram, presented in Figure 1, were plotted 
to discover the presence of different ME regions.  
   Livergol (0.5%.1%,2%and 4%) was added to oil phase and then S/Co mixture and a 
suitable amount of double distilled water were added to the mixture drop wise and continued 
by stirring the mixtures at ambient temperature until a uniform mixture was obtained. The 
components of the suitable formulation are 31% oil, 34% surfactant-cosurfactant, and 35% 
water. 
2.3. Droplet size examination 
   The mean droplet size of MEs were obtained using by SCATTER SCOPE 1 QUIDIX 
(South Korea) at 25˚C. 
2.4. pH and viscosity measurement 
   The viscosities and the pH values of the MEs were measured using by Brookfield 
viscometer (DV-II + Pro Brookfield, The USA, with a shear rate of 100 revolutions per 
minute (rpm)) and pH meter (Mettler Toledo SevenEasy, Switzerland) at 25˚C, respectively.  
 
 
Fig. 1. Pseudo-ternary phase (PTP) diagram of the system (olive oil; Tween 80: Span 20; propylene glycol/ 
water). Transparent MEs are represented by the dark area, with the remaining sectors of the PTP diagram 
representing cloudy (turbid) emulsions. 
 
2.5. Drugs, stimulants, and control reagent (vehicle) 
   Livergol, which is an extract of Silybum marianum (milk thistle) was purchased from an 
Iranian manufacturer (Barich Herbal Pharmaceuticals, Kashan, Iran). The component profile 
for this sample may be obtained on request from the manufacturer (Barich). The preparation 
of the extract for use as in the present study was conducted at the Department of 
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Pharmacognosy of the School of Pharmacy, Ahwaz Jundishapur Medical Science University. 
Briefly, 300 grams of powdered milk thistle extract was extracted in 90% ethanol for 3 days, 
and filtered. The filtrate was re-extracted with 90% ethanol three times. The pooled filtrate 
was concentrated to dryness using a vacuum evaporator (Adolph, Model 462, Germany). The 
dried extract was suspended in normal saline (NS) and prepared for administration to mice, as 
previously described[15]. 
   The composition of the LG formulation used in the present study was adjusted to 
approximately the same range of component composition as commercially available products 
marketed as a nutraceutical. A typical human single dose (in tablet form) contains 70 and 140 
mg of silymarin per tablet [16]. The main ingredients of this product are flavonolignan of S. 
marianum, such as silibinin, silychristin, silydianin, and 2-3 dehydrosilybin derivatives, 
collectively in whole fruit extract form called silymarin. The MEs vehicle without LG was 
administered to mice as a negative control treatment. BB was purchased from Sigma (St. 
Louis, Missouri, USA). Chemicals (methanol, ethanol, formalin, paraffin, and salts) were 
purchased from the local market in Iran. Before administration of BB to mice, the compound 
was dissolved in liquid paraffin (1/2 v/v, respectively). 
 
  2.6. Treatment group design, drug administration, and sample collection 
   Mice were randomly assigned to eight test groups of ten animals each, based on LG dosage. 
To determine the existence of a dose-responsive relationship between the quantity of LG 
administered and hepatotoxicity, members of each group were administered LG-
supplemented MEs treatments daily by oral gavage for 10 days, in a dose range of 0–400 
mg/kg LG body weight of each animal. On the 10thday of the study, 1 hour following the last 
dose of LG, each animal received ip injections of BB at a dosage of 0.36 ml/kg, body weight. 
   The groups were segregated according to the following treatment combinations: GROUP 1 
negative control animals (saline gavage): LG = 0 mg/kg, BB = 0; GROUP 2 (ME vehicle 
gavage): LG = 0 mg/kg, BB = 0; GROUP 3 (MEs gavage): LG = 400 mg/kg, BB = 
0;GROUP 4 (MEs gavage): LG = 0 mg/kg, BB = 0.36 ml/kg, ip; GROUP 5 (MEs gavage): 
LG = 50 mg/kg, BB = 0.36 ml/kg, ip; GROUP 6 (MEs gavage): LG = 100 mg/kg, BB = 0.36 
ml/kg, ip; GROUP 7 (MEs gavage): LG = 200 mg/kg, BB = 0.36 ml/kg, ip; GROUP 8 (MEs 
gavage): LG = 400 mg/kg, BB = 0.36 ml/kg, ip. 
   24 hours after the last dose (on the 11thday), mice were anesthetized with sodium 
pentobarbital (80 mg/kg, i.p) and sacrificed under anesthesia, followed by sample collection. 
Blood was collected from the jugular vein and placed at ambient room temperature 
(approximately 250C) for 40 minutes to allow clot formation. Defibrinated serum was 
extracted by centrifugation for 10 minutes at 2500 rpm. The livers were excised immediately 
after collection of blood, weighed, washed in ice cold saline, and stored in 10% neutral 
phosphate-buffered formalin for histological examination. 
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2.7. Analysis of samples for hepatotoxicity 
   5-μm thick histological sections were prepared from each liver sample, HE‐stained, and 
observed under a light microscope to evaluate the extent of BB-associated microstructural 
tissue damage in each dosage group, as described in previous studies by these authors[9, 13, 
17]The toxicogenic effects on liver metabolism were assessed by measurement of the 
activities of 3 hepatic enzymes known to increase in response to toxic insult: AST, ALT, 
ALP. They were assayed in mouse serum by the method of Reitman and Frankel [18], and 
ALP activity was estimated using King’s methodology[19]. 
 
2.8. Statistical analysis 
   All data are presented as mean ± standard error of mean (SEM). Statistical analysis was 
carried out with SPSS software, performing one-way ANOVA, followed by Tukey’s post-hoc 
test. Probability values <0.05 were considered the threshold for significant difference 
between the magnitude of differences between test groups versus negative control animals 
with respect to enzyme activities. Significance (p) values are shown for comparison of 
average enzyme activities for each LG-treated group with animals treated with BB only. P < 
0.05 is the threshold for significant difference between groups with respect to each outcome 
variable. 
 
3. Results 
3.1. Characterization of the Microemulsions 
   The mean droplet sizes of ME formulations in ratios of 0.5%, 1%, 2% and 4% are 26.3 ± 
0.9 nm, 19.5 ± 0.3, 25.3 ± 0.7 and 20.8 ± 0.7 nm, respectively. The ME formulations had the 
average viscosity of 50 ± 1 centipoises, and the average pH of 5.6 ± 0.2. 
 
3.2. Serum liver enzyme activities 
    The outcome of assays for serum liver enzyme activities in each dosage group of animals is 
shown in Table 1. As expected, the highest levels of AST, ALT, and ALP activation was 
observed in the blood of animals in Group IV, which had been administered 0.36 mg/kg of 
BB but no LG. The activities of each of these three enzymes in Group IV mice, which 
constitute positive controls, were significantly higher than corresponding activities in any of 
the other groups (p<0.05). Additionally, a trend for dose-responsive decrease in each enzyme 
was observed in animals receiving emulsions supplemented with LG in the dose range of 50 
mg/kg (Group V) through 400 mg/kg (Group VIII) (p<0.05). Finally, it was observed that no 
significant differences in the activities of any of the enzymes were observed in the 
comparison of Group I animals, which were administered NS gavage with corresponding 
activities in Group II mice, which were treated with the “blank” MEs vehicle. 
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 3.3. Effects of BB and LG on liver histopathology 
   Tissue from saline-treated mice shown in Figure 2A exhibits healthy ultrastructure, as 
expected. Likewise, hepatic tissue from mice treated with 400 mg/kg LG alone (2B) and the 
MEs vehicle alone (2C) appear healthy, also as expected. By contrast, examination of slides 
made from livers of mice receiving BB revealed pathological changes in tissue architecture. 
These effects are most pronounced in livers from mice receiving BB but no LG (2D). A dose-
responsive decrease in pathological changes in hepatic tissue architecture was observed in 
examination of mice receiving LG at 50 mg/kg (2E), 100 mg/kg (2F), 200 mg/kg (2G), and 
400 mg/kg (2H). 
 
 
 
Table1. Serum hepatic enzyme activity levels. Serum activities of AST, ALT and ALP  in mice 
treated for 10 days with gavage of NS, MEs vehicle (base), or MEs with 400 mg/kg LG, and ip 
injections of 0.36 ml/kg BB, plus 50, 100, 200, and 400 mg/kg LG (dispersed in MEs).Enzyme 
activity levels are expressed in International Units (IU) per liter of serum ± SEM. Significance (p) 
values are shown for comparison of average enzyme activities for each LG-treated group, including 
animals treated with BB only (Group IV).P< 0.05 is the threshold for significant difference between 
groups with respect to each outcome variable. 
Treatment Group(n =8 per group) AST(IU/l ± SEM) ALT(IU/l ± SEM) ALP(IU/l ± SEM) 
Group I 
NS vehicle, 0 mg/kg LG, 0 mg/kg BB 
226.70 ± 8.22b 
 
68.90 ± 7.18b 
 
175.40 ± 7.36b 
 
Group II 
MEs vehicle, 0 mg/kg LG, 0 mg/kg BB 
231.90 ± 5.64b 
 
72.10 ± 6.40b 
 
172.90 ± 7.14b 
 
Group III 
MEs vehicle., 400 mg/kg LG, 0 mg/kg BB 
223.5 ± 10.61b 
P=0.032 
67.20 ± 6.89b 
P=0.027 
171.50 ± 8.37b 
P=0.031 
Group IV 
MEs vehicle, 0 mg/kg LG, 0.36 mg/kg BB 
371.50 ± 27.15a 
 
128.70 ± 11.50a 
 
252.60 ± 12.16a 
 
Group V 
MEs vehicle, 50 mg/kg LG, 0.36 mg/kg BB 
347.10 ± 27.50a 
P=0.06 
119.90 ± 8.25a 
P=0.066 
235.30 ± 7.46a 
P=0.059 
Group VI 
MEs vehicle, 100 mg/kg LG, 0.36 mg/kg BB 
339.60 ± 25.43a,b 
P=0.030 
110.50 ± 9.37a,b 
P=0.034 
223.6 ± 7.7a,b 
P=0.039 
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Group VII 
MEs vehicle, 200 mg/kg LG, 0.36 mg/kg BB 
290.50 ± 16.24a,b 
P=0.032 
92.70 ± 10.91a,b 
P=0.029 
197.00 ± 11.03a,b 
P=0.032 
Group VIII 
MEs vehicle, 400 mg/kg LG, 0.36  mg/kg 
BB 
244.90 ± 12.59b 
P=0.036 
85.10 ± 8.49a,b 
P=0.038 
190.70 ± 9.58a,b 
P=0.028 
 
* p<0.05 in comparison with drug-free, saline-treated, negative control animals (Group I). 
**Significance of comparison with mice treated with BB, but not LG (Group IV). (a) Significance 
difference with control group (P< 0.05). (b) Significance difference with positive control (P< 0.05). 
(a, b) significance difference with control group and positive control (P< 0.05). 
 
 
Fig. 2. Histopathological evaluation of liver tissue.5-μm thick tissue sections harvested from Swiss 
Albino mice, HE-stained and formalin-fixed, and examined by light microscopy. Results shown 
correspond to hepatic tissue taken from animals treated by oral gavage for 10 days with NS or MEs 
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vehicle, with or without selected dosage of LG, followed by ip injection of 0.36 ml/kg BB or vehicle 
(MEs without LG), and sacrifice 24 hours after injections. Photographs at 400X magnification are 
shown for tissue from animals receiving the following treatment combinations: (A) NS, no BB; (B) 
MEs vehicle, no BB; (C) MEs with 400 mg/kg LG, no BB; (D) MEs vehicle, no LG, 0 0.36 ml/kg 
BB; (E) MEs with 50 mg/kg LG, 0 0.36 ml/kg BB; (F) MEs with 100 mg/kg LG, 0 0.36 ml/kg BB; 
(G) MEs with 200 mg/kg LG, 0 0.36 ml/kg BB; (H) and MEs with 400 mg/kg LG, 0 0.36 ml/kg BB. 
 
4. Discussion 
 
    The major outcomes of the present study include a clear demonstration that orally 
administered LG significantly suppresses BB-induced increases in serum activity of enzymes 
that correlate with liver toxicity: AST, ALT, ALP (Table 1), and hepatocellular injury, as 
demonstrated by histological analyses (Figure 2). Although the data shown here do not allow 
an in-depth mechanistic interpretation of the results, toxicological studies of yield some 
insight into the observed effects of BB on mouse livers in the present investigation, and into 
the capacity of LG to counteract them. BB is a well-known hepatotoxin, widely used to 
induce experimental liver injury [20]. 
    Metabolism of  BB  generates reactive species leading to oxidative stress and consequent 
hepatocellular damage[21], the extent of which may be easily monitored as a direct correlate 
of serum AST, ALT, and ALP activities[22].In the present study, elevated serum AST, ALT, 
and ALP activities observed after BB treatment (Table 1) are most likely due primarily to 
toxicant-mediated hepatocellular damage, demonstrated by histological examination (Figure 
2).The ability of LG to stimulate the observed protective effects reported here is an outcome 
that was expected, based on the known performance of the product[23, 24], and on previous 
studies of the efficacy of milk thistle extract in treatment of liver disease [4].  
    The physiological mechanisms underlying the observed effect may be estimated by 
considering the nature of cytoprotective phytochemicals produced by the plant. The best 
known bioactive compound in milk thistle is silibinin, a polyphenol produced by the plant 
with strongly hepatoprotective and anti-tumor properties[25, 26]. Milk thistle also contains 
structurally related polyphenols called (flavonolignans), including silydianin, silychristin, 
isosilychristin, the silybins and isosyilibins, and taxifolin, which is a highly potent 
cytoprotective flavonoid[27].  
   Microemulsions exhibit several advantages as a drug delivery system for instance, these are 
thermodynamically stable, require low energy level for formation, easy of manufacturing and 
improve drug solubility, bioavailability and efficacy. The aim of this work is to evaluate the 
hepatoprotective effect of LG loaded in MEs and to increase the oral bioavailability of LG in 
mice. Based on the results the efficacy of LG in MEs showed better drug solubility and 
permeability which lead to improve drug absorption among different biological membranes. 
   Due to very small particle size of MEs there would be high contact surface area between 
drug and gastrointestinal tract media. In previous studies[14, 28-31] we investigated MEs 
penetration through different biological membranes due to very small particle size of MEs 
and their biocompatibility with cellular barriers[32]. Poor effect of ME formulations on 
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hepatic enzymes activity have been proved that these formulations are not toxic and oral 
bioavailability of LG could be increased via this carrier system.  
   According to our result, the hepatoprotective effect of this formulation against BB toxicity 
has been conducted through the control release, high diffusion and absorption rates and 
improve and increase in oral bioavailability of active pharmaceutical agents.  
   Histopathology examination of livers showed that BB induced severe damages in tissue 
architecture, including swelling of hepatic cytoplasm, steatosis centrilobular, necrosis, 
inflammation, and congestion. Treatment with LG has improved hepatic damages due to BB 
severe degeneration and vacuolation of hepatocytes. LG administration can probably repair 
the hepatic tissue through the stimulation of protein synthesis and hepatocytes regeneration. 
   The results of the present study show that LG is a potent cytoprotectant agent with potential 
for broad clinical use. The ability of this formulation to significantly suppress expression of 
enzymes elevated in response to toxigenic damage, and also inhibit damage to liver tissue 
ultrastructure in BB-treated mice, demonstrates its medical value. An intriguing corollary use 
for this product is in preventive medicine. There are negligible adverse side effects associated 
with human consumption of Livergol. For this reason, it might be given prophylactically to 
persons at risk for toxic liver damage of bromobenzene. 
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